Annovis Bio

Annovis Bio develops medicines for brain diseases like Alzheimer’s and Parkinson’s. Its main drug aims to help people think and move better. The company’s work targets patients with memory and movement problems.

Brainy Business: Products and Services

• Buntanetap (Lead Drug): Oral medicine in trials for Alzheimer’s and Parkinson’s; targets adults with memory or movement loss. (0% of revenue; pre-commercial)
• ANVS405: Drug in development for brain injuries and stroke; aims to protect brain cells. (0% of revenue)
• ANVS301: Early-stage drug for late-stage Alzheimer’s and dementia; designed to improve thinking skills. (0% of revenue)

Growth Spurts: Expansion Moves

• Started pivotal Phase 3 trial for buntanetap in early Alzheimer’s in February 2025.
• Completed Phase 3 Parkinson’s study in December 2023; released results in July 2024.
• Raised $19.3 million in a public offering in February 2025.
• Set up a $50 million equity facility with Oppenheimer & Co. Inc. in December 2024.

What Makes Annovis Bio Stand Out

The company targets several brain disease proteins at once, not just one. Its main drug is designed to help both memory and movement. Annovis Bio operates with a small team and focuses on clinical research in the United States.

Five Things You Need to Know

• Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
• Operating loss was $-6 million in Q2 2025, improving 19.2% from Q2 2024.
• Cash and cash equivalents were $17.1 million as of June 30, 2025.
• Research and development expenses were $5.2 million in Q2 2025, down from $5.8 million in Q2 2024.
• Accumulated deficit reached $146.6 million as of June 30, 2025.

Bottom Line

Annovis Bio remains focused on developing new drugs for brain diseases. The company faces funding challenges but continues to advance its clinical programs.